Description
Numerous studies have been conducted to assess SARS-CoV-2 seroprevalence in the general community or in target populations. In May 2020, Cascais was the first Portuguese municipality to offer to the possibility of performing serological testing to SARS-CoV-2, together with a questionnaire to collect socio-demographic, clinical and behavioral (SDCB) data.In this cross-sectional study, with non-probabilistic volunteer sampling, a total of 19608 serological test results (almost 10% of the Cascais’ residents) were combined with SDCB data from the questionnaires, obtained between May 21st 2020 and February 12th 2021. The association between serological test outcome and SDCB factors was investigated.
From May to October 2020, during the relief stages after the first wave of the pandemic, the estimated seroprevalence was 1.39% (95% CI: 1.2 –1.58%). From October 2020 to February 2021, during the second and third waves, the seroprevalence was 9.44% (95% CI: 8.31–10.70%). SDCB factors that showed association with the outcome of the serological test included the place of residence and size of household. Seroprevalence did not differ significantly between chronically ill and non-ill, although it was lower in the chronically ill. About a quarter of those reporting previous confirmed SARS-CoV-2 infection did not have detectable anti-SARS-CoV-2 antibodies. From those with a reactive serological test, 30.6% (95% CI: 26.5 – 39.9%) reported not having had any symptom.
Place of residence and size of household were associated with SARS-CoV-2 serological testing results. Seroprevalence in non-chronically ill was higher suggesting a protective behavioral for exposure in these participants.
| Period | 21 Apr 2023 |
|---|---|
| Event title | 6º National Conference of Tropical Medicine |
| Event type | Conference |
| Location | Lisbon, PortugalShow on map |
| Degree of Recognition | National |